

Neurotech collaborates with University of Sydney in Rett syndrome program

- **International Rett Syndrome expert Dr Wendy Gold appointed to lead NTI164 mechanism of action studies**
- **Further characterisation of the mechanism of action of NTI164 follows a successful Phase 1 clinical study in Rett syndrome**
- **Rett syndrome is a rare and severe neurodevelopmental disorder with significant unmet need**

Neurotech International Limited (ASX: NTI) (“Neurotech” or “the Company”), a clinical-stage biopharmaceutical company focused on paediatric neurological disorders, is pleased to announce a research collaboration with The University of Sydney to advance the development of proprietary cannabinoid-based compound NTI164 for Rett syndrome.

The program will be led by Professor Wendy Gold, Head of School of Medical Sciences (interim), Faculty of Medicine and Health at the University of Sydney, an internationally recognised expert in human neuronal modelling of neurodevelopmental disorders, including Rett syndrome. Professor Gold brings international expertise in translating human neuronal models into mechanistic insight for neurodevelopmental disorders.

Preclinical observations to date suggest that NTI164 may exert potent, multi-modal activity across several key Rett-associated pathways. The University of Sydney collaboration will therefore focus on defining how NTI164 modulates fundamental disease mechanisms in this disease model.

The research will utilise human derived Rett syndrome neuronal models, enabling direct investigation of disease-relevant cellular, molecular, and functional abnormalities associated with the MECP2 deficiency.

These advanced human models provide a translationally relevant platform to interrogate disease mechanisms and therapeutic response.

Following the successful completion of its Phase 1 clinical study, Neurotech is now expanding its Rett syndrome program to further characterise the mechanism of action of NTI164 in human Rett disease models.

Rett syndrome, a rare and severe neurodevelopmental disorder with significant unmet medical need, is characterised by widespread disruption of gene regulation, mitochondrial dysfunction, impaired synaptic development and abnormal neuronal network activity. These core biological disturbances underpin the neurological and systemic manifestations of the disease.

Professor Gold commented: “We are very excited about this collaboration. These human neuronal systems allow Rett syndrome to be modelled with unprecedented biological relevance, enabling, for the first time, detailed investigation of disease mechanisms and therapeutic responses directly in neurons affected by Rett syndrome.”

Authority

This announcement was authorised for release by Anthony Filippis, Managing Director and CEO of Neurotech International Limited.

For further information contact us via info@neurotechinternational.com

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase III Clinical Study in ASD.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.